With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170911-92-9,tert-Butyl 4-(4-aminophenyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
2,4-Dichloro-5-(trifluoromethyl)pyrimidine (2.39 g, 11.0 mmol) was stirred in a 1 :1 f- BuOH: ,2-dichloroethane mixture (80 mL) at 0 C and a 1 .0 M ZnCI2 solution in diethyl ether (12.6 mL, 12.6 mmol) was added cautiously over 20 minutes and the reaction was left stirring at 0 C for 30 minutes. A solution of ferf-butyl 4-(4- aminophenyl)piperazine-1-carboxylate (/2) (2.92 g, 10.5 mmol) in 1 :1 f-BuOH.1 ,2- dichloroethane (40 mL) was added drop-wise over 15 minutes at 0 C followed by a solution of triethylamine (1.76 mL, 12.6 mmol) in 1 : 1 f-BuOH: 1 ,2-dichloroethane (40 mL) and the reaction was allowed to warm to room temperature and was stirred for 18 hours. The organic solvents were evaporated in vacuo and the crude yellow oily solid was suspended in water (400 mL), the suspension was sonicated for 30 minutes and the product was collected by filtration, the solid was washed with water (10 x 20 mL) and dried under a high vacuum to give the title compound (13) (4.75 g, 98% yield) as a beige solid; 1H NMR (400 MHz, oVDMSO) delta 10.45 (s, 1 H), 8.72 (s, 1 H), 7.50 (d, J = 8.5 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 3.50 – 3.42 (m, 4H), 3.09 – 3.02 (m, 4H), 1 .42 (s, 9H). LCMS Method C: H 6.56 min; m/z 456.2, 458.1 [M-H]”.
170911-92-9, The synthetic route of 170911-92-9 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; CANCER THERAPEUTICS CRC PTY LIMITED; HOLMES, Ian, Peter; BERGMAN, Ylva; LUNNISS, Gillian Elizabeth; NIKAC, Marica; CHOI, Neil; HEMLEY, Catherine Fae; WALKER, Scott Raymond; FOITZIK, Richard Charles; GANAME, Danny; LESSENE, Romina; WO2012/110773; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics